AI assistant
Sending…
Wave Life Sciences Ltd. — Director's Dealing 2019
Mar 12, 2019
31900_dirs_2019-03-11_61d66a3b-0178-4031-af84-d366b92883d9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Wave Life Sciences Ltd. (WVE)
CIK: 0001631574
Period of Report: 2019-03-07
Reporting Person: Panzara Michael A. (Franchise Lead, Neurology)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-03-07 | Ordinary Shares | A | 15000 | $0.00 | Acquired | 52388 | Direct |
| 2019-03-11 | Ordinary Shares | S | 7000 | $48.00 | Disposed | 45388 | Direct |
Footnotes
F1: Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 15, 2020 through February 15, 2023.
F2: Consists of sale of RSUs effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 19, 2018.
More from Wave Life Sciences Ltd.
Regulatory Filings
2026
May 18
Interim / Quarterly Report
2026
Apr 28
Regulatory Filings
2026
Apr 28
Regulatory Filings
2026
Apr 21
Regulatory Filings
2026
Apr 15
Major Shareholding Notification
2026
Mar 31
Director's Dealing
2026
Mar 31
Regulatory Filings
2026
Mar 26
Director's Dealing
2026
Feb 28
Annual Report
2026
Feb 26